48-Week effectiveness and tolerability of dolutegravir (DTG) + lamivudine (3TC) in antiretroviral-naïve adults living with HIV: A multicenter real-life cohort

  1. Cabello-Ubeda, A.
  2. de Quirós, J.C.L.B.
  3. Carbonero, L.M.
  4. Sanz, J.
  5. Vergas, J.
  6. Mena, Á.
  7. Torralba, M.
  8. Segurado, M.H.
  9. Pinto, A.
  10. Tejerina, F.
  11. Palmier, E.
  12. Gutiérrez, Á.
  13. Vázquez, P.
  14. Pulido, F.
  15. Górgolas, M.
Journal:
PLoS ONE

ISSN: 1932-6203

Year of publication: 2022

Volume: 17

Issue: 11 November

Type: Article

DOI: 10.1371/JOURNAL.PONE.0277606 GOOGLE SCHOLAR lock_openOpen access editor

Sustainable development goals

Data source: Scopus